EmpiraMed Inc., a digital health technology company in Maynard, was chosen by Happify Health to perform a clinical trial of a prescription digital therapy to treat depression and anxiety, according to a Tuesday press release.
The clinical trial would put the digital therapy under the consideration of U.S. Food & Drug Administration approval.
Known as DTx, the digital treatment is the first and only of its kind to treat patients with major depressive disorder or generalized anxiety disorder.
EmpiraMed was selected due to a high level of patient engagement, according the statement.
Happify Health is a global healthcare platform based in New York City, which uses software to help improve mental and physical health outcomes.
